Return to Clinical Trials

Intravenous Administration In Combination With Docetaxel - United Kingdom

In December 2008, Oncolytics announced that it had completed enrolment in its U.K. trial using intravenous administration of REOLYSIN® in combination with docetaxel. Positive results were announced in November 2008. Of 11 evaluable patients, nine patients had stable disease or better for more than 4 cycles.

The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN® when administered in combination with docetaxel. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

See related press releases and documents:

December 18, 2008 - Oncolytics Biotech Inc. Completes Patient Enrolment in Two U.K. REOLYSIN® Combination Therapy Clinical Trials --Company to Host Conference Call to Update Clinical Program

A Phase I Study To Evaluate Systemic Wild-Type Reovirus (Reolysin®) In Combination With Docetaxel In Patients
With Advanced Malignancies

November 3, 2008 - Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN® and Docetaxel Results at iSBTc Annual Meeting

August 11, 2008 - Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN®/Docetaxel Trial

July 23, 2007 - Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN®/Docetaxel trial

January 3, 2007 - Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Docetaxel